Alignment Healthcare, Inc. Common Stock
ALHC
$12.76
-2.07%
Alignment Healthcare, Inc. is a next-generation healthcare platform that provides Medicare Advantage plans to seniors, integrating a proprietary technology platform with a clinical model to improve health outcomes and consumer experience. As a consumer-centric, direct-to-consumer player in the Medicare Advantage market, it differentiates itself through its technology-enabled care model and focus on senior populations. The company is currently navigating a period of significant growth, evidenced by a 44.4% year-over-year revenue increase in its latest quarter, while also managing the transition to profitability, as recent quarters have shown mixed earnings. Investor attention is centered on the company's ability to sustain its growth trajectory, improve margins, and capitalize on favorable regulatory tailwinds, such as the recent CMS Medicare Advantage payment increase, despite recent insider selling and stock price volatility.…
ALHC
Alignment Healthcare, Inc. Common Stock
$12.76
Related headlines
ALHC 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Alignment Healthcare, Inc. Common Stock's 12-month outlook, with a consensus price target around $24.08 and implied upside of +88.7% versus the current price.
Average Target
$24.08
0 analysts
Implied Upside
+88.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$16 - $30
Analyst target range
Analyst coverage is moderate, with 13 analysts providing ratings, but the consensus recommendation is not available, and the distribution of Buy/Hold/Sell is not provided. The average target price is $24.08, implying an upside of approximately 77.8% from the current price of $13.54, indicating a bullish sentiment among analysts. The target price range spans from a low of $16.00 to a high of $30.00, with the low target still representing an 18.2% upside, suggesting that even the most bearish analyst sees value at current levels. The wide spread between low and high targets (87.5% difference) reflects high uncertainty about the company's future performance, likely due to its growth stage and the evolving regulatory environment. Recent ratings actions have been mixed, with JP Morgan upgrading from Neutral to Overweight in November 2025, while UBS has maintained a Neutral stance, and KeyBanc upgraded from Sector Weight to Overweight in August 2025, indicating a generally positive but cautious outlook.
Bulls vs Bears: ALHC Investment Factors
ALHC presents a classic high-growth, high-risk investment profile. The bull case rests on exceptional revenue growth (44.4% YoY), emerging profitability, and a favorable regulatory environment, while the bear case is anchored by a persistent downtrend, thin margins, high leverage, and insider selling. Currently, the bearish evidence appears stronger given the stock's 33% YTD decline and proximity to its 52-week low, which suggests the market is pricing in significant execution risk. The central tension is whether ALHC can convert its rapid top-line growth into sustainable bottom-line profitability—if it does, the stock is deeply undervalued at 0.99x sales; if it fails, the current valuation could still prove too rich. The resolution of this margin expansion question will likely determine the stock's trajectory over the next 12 months.
Bullish
- Revenue Growth Accelerating: Q4 2025 revenue surged 44.4% YoY to $1,012.8M, up from $701.2M in Q4 2024, demonstrating robust membership expansion and strong execution in the Medicare Advantage market. This growth rate significantly outpaces the broader managed care sector, indicating successful market share gains.
- Path to Profitability Emerging: After posting net losses in Q1 2025 (-$9.1M) and Q4 2025 (-$11.0M), the company achieved profitability in Q2 2025 ($15.7M) and Q3 2025 ($3.7M), showing that its operating model can generate positive earnings. The TTM net margin improved to -0.02%, a dramatic improvement from -4.4% in Q4 2024.
- Analyst Targets Imply Significant Upside: The average analyst target price of $24.08 represents a 77.8% upside from the current price of $13.54, with even the lowest target of $16.00 implying an 18.2% gain. This suggests that sell-side analysts see substantial value in the stock at current levels, despite recent market pessimism.
- Favorable Regulatory Tailwinds: CMS announced a larger-than-expected Medicare Advantage payment increase for 2027, which boosts revenue visibility and margins across the sector. This regulatory development directly benefits ALHC's core business model and could improve profitability in the coming years.
Bearish
- Stock in Sustained Downtrend: ALHC has fallen 33.0% YTD and 16.9% over the past year, dramatically underperforming the S&P 500's +18.65% gain. The stock trades near its 52-week low of $12.70, just 6.7% above it, reflecting persistent selling pressure and negative investor sentiment.
- Thin and Volatile Margins: Gross margin contracted to 10.5% in Q4 2025 from 12.6% in Q3 2025, while operating margin remains razor-thin at 0.37% TTM. The Medicare Advantage business is highly cost-sensitive, and any adverse claims experience or pricing pressure could quickly erode profitability.
- High Leverage and Balance Sheet Risk: Debt-to-equity ratio stands at 1.84x, indicating significant leverage for a company still transitioning to sustained profitability. This financial structure increases vulnerability to interest rate fluctuations and could constrain strategic flexibility if cash flows deteriorate.
- Insider Selling Signals Caution: The vice chairman sold 25,000 shares in June 2026, adding to a pattern of insider selling that investors should treat as a cautionary signal. While these sales may be part of planned trading programs, they often indicate that insiders believe the stock is fairly valued or overvalued.
ALHC Technical Analysis
Alignment Healthcare's stock has been in a pronounced downtrend over the past year, with a 1-year price change of -16.93%, significantly underperforming the S&P 500's +18.65% gain. The current price of $13.54 sits near the lower end of its 52-week range, at approximately 6.7% above the 52-week low of $12.70 and 46.1% below the 52-week high of $25.12. This positioning near the lows suggests a market that is pricing in significant pessimism, potentially presenting a value opportunity if fundamentals stabilize, but also carrying the risk of a falling knife if the downtrend persists.
Beta
1.11
1.11x market volatility
Max Drawdown
-48.0%
Largest decline past year
52-Week Range
$13-$25
Price range past year
Annual Return
-22.4%
Cumulative gain past year
| Period | ALHC Return | S&P 500 |
|---|---|---|
| 1m | -3.3% | -1.6% |
| 3m | -35.4% | +2.2% |
| 6m | -24.9% | +14.4% |
| 1y | -22.4% | +16.2% |
| ytd | -36.9% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ALHC Fundamental Analysis
Revenue growth has been robust, with the most recent quarter (Q4 2025) reporting revenue of $1,012.8 million, a 44.4% year-over-year increase, and sequential growth from $993.7 million in Q3 2025. This growth is driven by strong performance in both health care premium revenue ($425.8 million) and capitation revenue ($33.2 million), indicating broad-based expansion. However, the company remains unprofitable on a trailing twelve-month basis, with a net margin of -0.02% and a net loss of $11.0 million in Q4 2025, though it achieved profitability in Q2 and Q3 2025, suggesting a path toward sustained profitability. Gross margin has been volatile, at 10.5% in Q4 2025, down from 12.6% in Q3 2025, reflecting the competitive and cost-sensitive nature of the Medicare Advantage business.
Quarterly Revenue
$1.0B
2025-12
Revenue YoY Growth
+44.4%
YoY Comparison
Gross Margin
10.5%
Latest Quarter
Free Cash Flow
$123672000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ALHC Overvalued?
Given that Alignment Healthcare has negative trailing earnings (net income of -$11.0 million in Q4 2025), the price-to-sales (PS) ratio is the most appropriate valuation metric, as it allows for comparison across companies regardless of profitability. The current PS ratio is 0.99x, which is significantly lower than the industry average of 3.86x (based on historical data), indicating a substantial discount. This discount may be justified by the company's thin margins and competitive pressures, but it also suggests the market is pricing in limited growth or higher risk. The forward PE ratio of 17.99x implies that analysts expect earnings to improve dramatically, which is consistent with the company's recent quarterly profitability and growth trajectory, but it also highlights the market's optimism for a turnaround.
PE
-5337.8x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
80.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are substantial. ALHC carries a debt-to-equity ratio of 1.84x, which is high for a company that only recently achieved quarterly profitability, and its TTM net margin of -0.02% leaves little room for error. The company's gross margin is volatile, swinging from 12.6% in Q3 2025 to 10.5% in Q4 2025, reflecting the competitive and cost-sensitive nature of Medicare Advantage. Additionally, free cash flow of $123.7M TTM is positive but modest relative to the company's $3.9B market cap, and the negative EPS in Q4 2025 (-$0.05) highlights that profitability is not yet consistent. If medical cost trends worsen or membership growth slows, the company could quickly return to deeper losses, given its thin operating margin of 0.37%.
Market and competitive risks are equally significant. ALHC trades at a PS ratio of 0.99x versus an industry average of 3.86x, which could indicate either a value opportunity or a value trap if the market is correctly pricing in structural disadvantages. The stock's beta of 1.13 suggests above-market volatility, and its 33% YTD decline versus the S&P 500's +12.94% gain shows severe underperformance, implying that investors are rotating out of small-cap healthcare names. Competitive pressure from larger players like UnitedHealth and Humana, which have greater scale and negotiating power, poses a constant threat to ALHC's market share and margins. Regulatory changes to Medicare Advantage reimbursement rates, while currently favorable, could reverse and compress margins across the sector.
In a worst-case scenario, ALHC could face a perfect storm of rising medical costs, membership attrition, and a regulatory clampdown on Medicare Advantage payments. If the company fails to sustain its recent profitability and posts consecutive quarterly losses, the stock could revisit its 52-week low of $12.70, representing a 6.2% downside from the current price of $13.54. However, given the stock's historical volatility and the 48% max drawdown over the past year, a more severe decline to the $10-$11 range is plausible if the market loses confidence in the growth story. This would represent a potential loss of 20-25% from current levels, underscoring the high-risk nature of this investment.